InnoCare Pharma Limited (OTCMKTS:INCPF – Get Free Report) was the target of a significant drop in short interest in the month of December. As of December 31st, there was short interest totalling 3,295 ...
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...
(IN BRIEF) AstraZeneca’s Calquence (acalabrutinib) has been approved by the U.S. FDA for the first-line treatment of adult patients with previously untreated mantle cell lymphoma (MCL) who are ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback